%0 Journal Article
%T Exploratory study of blood biomarkers in patients with post-stroke epilepsy.
%A Abraira L
%A López-Maza S
%A Quintana M
%A Fonseca E
%A Toledo M
%A Campos-Fernández D
%A Lallana S
%A Grau-López L
%A Ciurans J
%A Jiménez M
%A Becerra JL
%A Bustamante A
%A Rubiera M
%A Penalba A
%A Montaner J
%A Álvarez Sabin J
%A Santamarina E
%J Eur Stroke J
%V 0
%N 0
%D 2024 Apr 1
%M 38557165
%F 5.894
%R 10.1177/23969873241244584
%X <B>UNASSIGNED: </B>In addition to clinical factors, blood-based biomarkers can provide useful information on the risk of developing post-stroke epilepsy (PSE). Our aim was to identify serum biomarkers at stroke onset that could contribute to predicting patients at higher risk of PSE.<BR><B>UNASSIGNED: </B>From a previous study in which 895 acute stroke patients were followed-up, 51 patients developed PSE. We selected 15 patients with PSE and 15 controls without epilepsy. In a biomarker discovery setting, 5 Olink panels of 96 proteins each, were used to determine protein levels. Biomarkers that were down-regulated and overexpressed in PSE patients, and those that showed the strongest interactions with other proteins were validated using an enzyme-linked immunosorbent assay in samples from 50 PSE patients and 50 controls. A ROC curve analysis was used to evaluate the predictive ability of significant biomarkers to develop PSE.<BR><B>UNASSIGNED: </B>Mean age of the PSE discovery cohort was 68.56 ± 15.1, 40% women and baseline NIHSS 12 [IQR 1-25]. Nine proteins were down-expressed: CASP-8, TNFSF-14, STAMBP, ENRAGE, EDA2R, SIRT2, TGF-alpha, OSM and CLEC1B. VEGFa, CD40 and CCL4 showed greatest interactions with the remaining proteins. In the validation analysis, TNFSF-14 was the single biomarker showing statistically significant downregulated levels in PSE patients (p = 0.006) and it showed a good predictive capability to develop PSE (AUC 0.733, 95% CI 0.601-0.865).<BR><B>UNASSIGNED: </B>Protein expression in PSE patients differs from that of non-epileptic stroke patients, suggesting the involvement of several different proteins in post-stroke epileptogenesis. TNFSF-14 emerges as a potential biomarker for predicting PSE.